IONIQ Sciences, Inc. recently announced that Raphael E. Pollock, MD, PhD, FACS has joined its Medical Advisory Committee. Dr. Pollock is an award-winning surgical oncologist, extensively published physician- scientist, Professor Emeritus in the Department of Surgical Oncology at MD Anderson Cancer Center and currently the Director of The Ohio State University Comprehensive Cancer Center (OSUCCC).
IONIQ is developing a rapid and non-invasive multi-cancer screen for early detection that has the potential to expand the therapeutic window, dramatically improve survivability and reduce the cost of healthcare.
Mr. Jared Bauer, IONIQ Sciences CEO, stated, “We are honored to welcome Dr. Pollock to our Medical Advisory Committee as we expand from our initial planned product, the IONIQ ProLung TestTM for lung cancer, to a single non-invasive screen for multiple cancers. With more than two decades of surgical oncology and research experience, we expect Dr. Pollock can provide us with invaluable insight into the physiological effects of numerous types of cancers, as well as the different approaches to cancer management. We believe Dr. Pollock’s contributions will accelerate our mission to develop and commercialize a modern solution for the early detection of multiple cancers and can monitor minimal residual disease.”
Dr. Pollock shared, “I am delighted to join IONIQ’s Medical Advisory Committee because detecting cancer at its earliest, most-treatable stages when lives can be saved has profound value to society. Simply put, early detection matters most. Oncology research has been an important part of my career. I believe in the work that IONIQ Sciences is doing and want to be a part of it.”
IONIQ Science’s first product utilizing its proprietary analytic platform, the IONIQ ProLung TestTM for lung cancer, has been designated a Breakthrough Device by the U.S. FDA. IONIQ Sciences is also a key supporter and proud sponsor of Utah’s BioHive, one of the nation’s fastest growing life sciences hubs.
“The evolution of IONIQ Sciences and its innovative cancer screening technology is a testament to the company’s leadership and the team’s commitment to advancing cancer detection,” said Kelvyn Cullimore, president and CEO of BioUtah.
For further information about IONIQ Sciences, Inc., please contact:
Andy Robertson | 1-801-736-0729 | acr@IONIQsciences.com IONIQ Sciences, Inc., Vice President of Business Development IONIQ Sciences, Inc.
350 W. 800 N., Suite 214
Salt Lake City, Utah 84103 USA www.IONIQsciences.com
Follow IONIQ Sciences, Inc. on Twitter, Facebook and LinkedIn: @IONIQSciences